About FDA
-
Drug Alert and Quality Risk Communications
-
Quality Risk Communications
- Assuring the Microbial Quality of Human Topical Antiseptic Products Through Robust Design and Manufacturing (See questions 11-13)
12/21/2011 - Preventing Non-Sterility Risks in Manufacturing Processes Used to Produce Large Volume Parenteral IV Bags (See questions 12-13)
7/5/2011 FDA Drug Safety Communication: Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone
5/6/2011- FDA News Release: FDA reminds health care professionals about safe use of non-sterile alcohol prep pads
2/1/2011 Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs
3/25/2011Advisory to Drug and Dietary Supplement Manufacturers, Compounding Pharmacies and Distributors of Excipients and Dietary Ingredients – FDA Detects High Levels of Peroxide in Crospovidone
10/21/2010- FDA Public Health Alert: Healthcare Professionals Warned Not To Use Certain Intravenous Metronidazole, Ondansetron, and Ciprofloxacin Due To Potential Microbiological Contamination
6/1/2010 - FDA's Questions and Answers (See Question 5-10) concerning drug contamination with 2,4,6-tribromoanisole (TBA)
3/12/2010
-
-
-
